iSpeak Blog

Contamination Control Strategies Sterile and Non-Sterile Manufacturers

Robert L. Iser, M.S.
Quality Manufacturing

As part of the planning committee, I’m very pleased to share this year’s theme for the 2018 ISPE Quality Manufacturing Conference, June 4-6 in Arlington, VA: Manufacturing and Quality: Present and Future Opportunities to Ensure Continuous Improvement; and we have put together three very interesting and timely tracks on Regulatory, Quality and Manufacturing, and Facilities and Equipment topics.

One session that I am very excited about is the one centered on Contamination Control Strategies. The session will include perspectives from experts in the pharma industry and the U.S. FDA; and will delve into Contamination Control Strategies for sterile and non-sterile manufacturers as an essential consideration for preventing product contamination. Pharma industry experts will share successful ways to communicate and manage contamination controls, with real-life examples.

Attendees will also have a chance to participate in a Q&A session that poses questions such as:

  • Do you have a dedicated Contamination Control lead or department?
  • What is the leading root cause for final product contamination at your company?
  • Do you have process risk assessments that include microbial ingress and contamination risks?

I am really looking forward to attending this session as part of the 2018 ISPE Quality Manufacturing Conference and hope that you will join me in June.

Best Regards

The ISPE Quality Manufacturing Conference is the foremost pharmaceutical quality event of the year. It provides a unique forum for attendees and speakers from industry, academia, and regulatory to address areas for opportunities to assure innovation and continuous supply of high-quality products to our patients.

Here’s what you can expect:

  • Dynamic keynote presentations featuring leaders from leading experts in FDA, MHRA, and Industry.
  • Content-rich sessions led by industry experts—introducing the latest in leading edge approaches in international regulatory convergence, quality and manufacturing potential, and facilities and equipment innovation
  • A featured session dedicated to the success of Women in Pharma®
  • Strong regulatory participation throughout the sessions, including FDA, MHRA (UK), and PMDA (Japan), culminating in a final interactive global regulatory forum where participants have the opportunity to ask questions directly to regulators.

Register by Monday, 26 March to take advantage of our lowest rates — saving you $400 or more!

Register Now!